Eascra Biotech

Eascra Biotech is a nanomedicine company that specializes in DNA-inspired synthetic molecular formulations known as Janus base nanoparticles (JBNps). These proprietary, rod-shaped nanoparticles mimic the structure of DNA and are designed to provide a versatile, stable delivery platform for a variety of therapeutic cargoes, including mRNA, siRNA, gene-editing tools, proteins, and peptides. By leveraging their unique morphology and chemical properties, JBNps are engineered to penetrate hard-to-reach tissues—such as articular cartilage and dense extracellular matrix-rich solid tumors—more effectively than traditional lipid nanoparticles. A key differentiator of the JBNp technology is its ability to maintain drug bioactivity and stability at room temperature, which helps eliminate complex cold-chain storage requirements.

The company focuses on applications in regenerative medicine, musculoskeletal diseases, and oncology, with specific efforts directed toward cartilage repair and the treatment of solid tumors. Eascra actively explores the potential of in-space manufacturing for its nanotechnology, having conducted multiple research missions to the International Space Station to study particle production in microgravity. Supported by various grants from organizations such as the National Science Foundation, NASA, and the U.S. Air Force, the company aims to modernize drug delivery systems to improve patient outcomes, reduce systemic toxicity, and advance commercial medical applications in the Low Earth Orbit economy.